Andras Masszi
Budapest, BU 1122, Hungary
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 15 publications
Ixazomib-Lenalidomide-Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma: A Hungarian Real-World Analysis.
Journal: Journal of clinical medicine
Published: December 01, 2025
Common variation at 1q23.3, 2p23.3, 2q33.3, and 2p21 influences risk of acute myeloid leukemia.
Journal: Blood
Published: August 19, 2025
Common variation at 1q23.3, 2p23.3, 2q33.3, and 2p21 influences the risk of acute myeloid leukemia.
Journal: Blood
Published: August 19, 2025
Resistance mechanisms and clonal dynamics in mantle cell lymphoma treated with sequential BTKi and venetoclax therapy.
Journal: The Journal of pathology
Published: January 07, 2025
How did the survival of acute myeloid leukemia change over the last ten years in our unit?
Journal: Orvosi hetilap
Published: July 27, 2023
Low-burden TP53 mutations represent frequent genetic events in CLL with an increased risk for treatment initiation.
Journal: The journal of pathology. Clinical research
Published: July 26, 2023
Parallel testing of liquid biopsy (ctDNA) and tissue biopsy samples reveals a higher frequency of EZH2 mutations in follicular lymphoma.
Journal: Journal of internal medicine
Published: June 01, 2023
Landscape of BCL2 Resistance Mutations in a Real-World Cohort of Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Treated with Venetoclax.
Journal: International journal of molecular sciences
Published: February 02, 2023
Revealing a Phenotypical Appearance of Ibrutinib Resistance in Patients With Chronic Lymphocytic Leukaemia by Flow Cytometry.
Journal: Pathology oncology research : POR
Published: June 17, 2022
Author Correction: Genome-wide association study identifies susceptibility loci for acute myeloid leukemia.
Journal: Nature communications
Published: January 05, 2022
Last Updated: 09/26/2026